Panax notoginseng-Paris polyphylla supramolecular complex, preparation method, cosmetic product and application thereof

Abstract

This invention provides a Panax notoginseng-Paris polyphylla supramolecular complex, its preparation method, cosmetic products, and applications. The Panax notoginseng-Paris polyphylla supramolecular complex is a complex formed by non-covalent bonding of Panax notoginseng extract (as the host molecule) and Paris polyphylla extract (as the guest molecule), with the host molecule encapsulating the guest molecule structure. The Panax notoginseng-Paris polyphylla supramolecular complex of this invention not only improves the water solubility of Paris polyphylla extract but also increases its skin permeability and reduces its cytotoxicity. The preparation method of this invention utilizes the synergistic effect of the active ingredients, resulting in strong compatibility and synergistic efficacy. It also slows down the release time of the active ingredients, extends their shelf life, and features a simple and easy-to-control process, stable granulation effect, and low production cost.

Description

Technical Field

[0001] This invention belongs to the field of cosmetics, specifically relating to a Panax notoginseng-Paris polyphylla supramolecular complex, its preparation method, beauty products and applications. Background Technology

[0002] In a broad sense, *Paris polyphylla* refers to plants of the genus *Paris* in the family Veratraceae. There are approximately 26 species of *Paris polyphylla* worldwide, mainly distributed in tropical and temperate regions of Eurasia, with 22 species found in my country. Currently, the species used in cosmetics are *Paris polyphylla*, *Paris globosum*, and *Paris yunnanensis*, collectively referred to here as *Paris polyphylla* extracts. Modern research shows that the main chemical components of *Paris polyphylla* are steroidal saponins, flavonoids, and triterpenoids, which possess anti-inflammatory, antibacterial, sedative, hemostatic, and antitumor effects. However, according to the pharmacopoeia, Paris polyphylla has a slight toxicity. Our previous studies on the cytotoxicity of Paris polyphylla extract on immortalized epidermal cells showed that when the concentration of Paris polyphylla extract exceeded 4 μg / mL, it exhibited cytotoxicity with an IC50 of 10.21 μg / mL. Clinical use has also shown that excessive intake can lead to adverse reactions such as nausea, vomiting, and diarrhea. Studies on mice administered total saponins of Paris polyphylla by gavage showed that some mice immediately developed diarrhea, as well as adverse reactions such as decreased activity, curling up, and restlessness. Mice in the high-dose group also showed hypothermia and cyanosis around the mouth.

[0003] Paris polyphylla extract is mainly used in the cosmetics industry for its anti-inflammatory, antibacterial, soothing, and moisturizing effects. However, its application is limited by factors such as high cytotoxicity and poor transdermal absorption. Currently, improving the transdermal absorption and reducing cytotoxicity of Paris polyphylla extract are the main problems that need to be solved for its application in the cosmetics industry.

[0004] Currently known techniques for preparing active ingredient complexes mainly include ethanol injection and thin-film dispersion. However, both methods are relatively complex and not conducive to large-scale production. Furthermore, organic solvents need to be added during the preparation process, and the presence of residual organic solvents can cause supramolecular toxicity, which is harmful to the human body.

[0005] The urgent problem to be solved is to provide a supramolecular complex containing Paris polyphylla active ingredients that has a simple preparation method, no risk of solvent residue, and good transdermal absorption effect. Summary of the Invention

[0006] Therefore, the purpose of this invention is to overcome the deficiencies in the prior art and provide a Panax notoginseng-Paris polyphylla supramolecular complex, its preparation method, cosmetic products, and applications. This invention employs natural composite supramolecular technology, utilizing the compatibility of different types of natural products to form a supramolecular structure through spontaneous non-covalent bonding. A safe and highly soluble Panax notoginseng extract is selected as a carrier to encapsulate the Paris polyphylla extract, thus preparing the Panax notoginseng-Paris polyphylla supramolecular complex. This reduces the cytotoxicity of the Paris polyphylla extract and increases its transdermal absorption and water solubility. Compared to current main methods for preparing supramolecular complexes, such as liposomes, microcapsules, and chlorophyll, this method uses only Panax notoginseng extract and Paris polyphylla extract as active ingredients during production, without adding any excipients or organic solvents. The process is simple, the production cost is low, and there are no issues such as organic solvent residue.

[0007] Before describing the content of this invention, the following terms are defined as follows:

[0008] The term "total saponins of Paris" refers to the total saponins extracted from the dried rhizomes of plants belonging to the genus Paris (Liliaceae or Veratrum family, depending on the classification system, Paris belongs to different families), including Paris saponin I, Paris saponin II, diosgenin, Paris saponin V, Paris saponin VI, Paris saponin VII, Paris saponin H, diosgenin fibrous glycoside, and Paris saponin D.

[0009] The term "PDI" refers to the Polymer Dispersion Index, which describes the molecular weight distribution of a polymer.

[0010] The term "supramolecular complex" refers to a complex consisting of a host active molecule I and a guest active molecule II (hereinafter referred to as active molecules I and II), wherein active molecule I is a macrocyclic molecule with a hydrophilic / hydrophobic cavity structure for embedding the guest active molecule therein; and active molecule II is the active ingredient to be delivered.

[0011] The term "β-glucan" refers to a natural product, a polysaccharide composed of glucose molecules linked by β-1,3- and β-1,6- bonds, also known as "immune gold".

[0012] The term "coenzyme Q10" refers to a coenzyme found in all eukaryotes that perform aerobic respiration; it is also known as ubiquinone or coenzyme Q.

[0013] The term "EGCE" refers to epigallocatechingallate.

[0014] To achieve the above objectives, a first aspect of the present invention provides a Panax notoginseng-Paris supramolecular complex, wherein the Panax notoginseng-Paris supramolecular complex is a complex in which the host molecule encapsulates the guest molecule structure, formed by non-covalent bonding of Panax notoginseng extract as the host molecule and Paris extract as the guest molecule.

[0015] The particle size of the Panax notoginseng-Paris polyphylla supramolecular complex is 100-1000 nm, preferably 200-900 nm, more preferably 200-870 nm, and most preferably 200-500 nm.

[0016] Preferably, the Panax notoginseng extract is a water extract of Panax notoginseng, more preferably a polysaccharide extract or oligosaccharide extract of Panax notoginseng obtained by water extraction; and / or

[0017] Preferably, the Paris polyphylla extract is an alcoholic extract of Paris polyphylla, and its main components are preferably selected from one or more of the following: total saponins of Paris polyphylla, saponin I, saponin II, diosgenin, saponin V, saponin VI, saponin VII, saponin H, diosgenin, and saponin D; more preferably selected from one or more of the following: total saponins of Paris polyphylla, saponin I, saponin II, saponin VI, saponin VII, and saponin H; even more preferably selected from one or more of the following: total saponins of Paris polyphylla, saponin I, saponin VII, and saponin H; and even more preferably selected from one or more of the following: total saponins of Paris polyphylla, saponin H, and saponin I.

[0018] According to a first aspect of the present invention, a Panax notoginseng-Paris polyphylla supramolecular complex, wherein,

[0019] The Panax notoginseng-Paris polyphylla supramolecular complex is a spherical or ellipsoidal inclusion;

[0020] The PDI of the Panax notoginseng-Paris polyphylla supramolecular complex is <0.5, preferably <0.45, more preferably <0.4, and most preferably <0.3;

[0021] The encapsulation efficiency of the Panax notoginseng-Paris polyphylla supramolecular complex is >65%, preferably >70%, more preferably >75%; and / or

[0022] The mass ratio of the guest molecule to the host molecule is 1:1 to 800, preferably 1:1 to 600, and more preferably 1:4 to 600.

[0023] According to a first aspect of the present invention, a Panax notoginseng-Paris polyphylla supramolecular complex, wherein,

[0024] The Paris polyphylla extract is selected from one or more of the following: Paris polyphylla longipeta extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract; and / or

[0025] The Panax notoginseng extract is selected from one or more of the following: Panax notoginseng stem and leaf water extract, Panax notoginseng root water extract, Panax notoginseng flower extract, Panax notoginseng whole plant water extract, preferably Panax notoginseng root water extract or Panax notoginseng whole plant water extract, and most preferably Panax notoginseng root water extract.

[0026] A second aspect of the present invention provides a method for preparing the Panax notoginseng-Paris polyphylla supramolecular complex described in the first aspect, the method comprising the following steps:

[0027] (1) Prepare the guest molecule Paris polyphylla extract solution and the host molecule Panax notoginseng extract solution respectively;

[0028] (2) The guest molecule Paris polyphylla extract solution and the host molecule Panax notoginseng extract solution prepared in step (1) are mixed and dispersed and homogenized at high speed to obtain a host-guest suspension.

[0029] (3) The host-guest suspension prepared in step (2) was homogenized under high pressure to obtain a host-guest supramolecular solution; and

[0030] (4) The host-guest supramolecular solution prepared in step (3) is dried to obtain the supramolecular complex.

[0031] According to a second aspect of the method of the present invention, in step (1):

[0032] When the main molecule is Panax notoginseng aqueous extract, the preparation method of the main molecule Panax notoginseng extract solution includes: adding pure water to the Panax notoginseng aqueous extract to obtain the main molecule solution; and / or

[0033] When the guest molecule is a Paris polyphylla ethanol extract, the preparation method of the guest molecule Paris polyphylla extract solution includes: adding pure water at 50℃~90℃, preferably pure water at 70℃~80℃, to the Paris polyphylla ethanol extract to obtain the guest molecule solution.

[0034] According to a second aspect of the method of the present invention, in step (1):

[0035] The concentration of the main molecule, Panax notoginseng extract solution, is 1–200 g / L, preferably 1–150 g / L, more preferably 10–100 g / L; and / or

[0036] The concentration of the guest molecule Paris polyphylla extract solution is 1–200 g / L, preferably 1–100 g / L, and more preferably 5–50 g / L.

[0037] According to the method of the second aspect of the present invention, in step (2):

[0038] The homogenization rotation speed is 0–10000 r / min, preferably 3000–10000 r / min, more preferably 3000–9000 r / min; and / or

[0039] The homogenization time is 0–60 min, preferably 5–40 min, and more preferably 10–25 min.

[0040] According to the method of the second aspect of the present invention, wherein,

[0041] In step (3):

[0042] The pressure of the high-pressure homogenizer is 10 to 1500 Bar, preferably 100 to 1000 Bar, and more preferably 400 to 700 Bar;

[0043] The homogenization cycle is 1 to 30 times, preferably 5 to 25 times, more preferably 10 to 20 times; and / or

[0044] In step (4), the drying method is selected from one or more of the following: vacuum freeze drying, spray drying, and reduced pressure drying, preferably vacuum freeze drying or spray drying, and most preferably vacuum freeze drying.

[0045] A third aspect of the present invention provides a beauty product comprising the Panax notoginseng-Paris polyphylla supramolecular complex described in the first aspect;

[0046] Preferably, the beauty product further comprises one or more of the following: moisturizing ingredients, whitening ingredients, anti-aging ingredients, sun protection ingredients, repairing ingredients, acne-reducing ingredients, and soothing ingredients; wherein:

[0047] The moisturizing ingredients are preferably selected from one or more of the following: hyaluronic acid, amino acids, provitamin B, allantoin, ceramide, hyaluronic acid, glycerin, sodium alginate, tremella polysaccharide, seaweed polysaccharide, squalane, beta-glucan, sodium pyrrolidone carboxylate, collagen, lactic acid, petrolatum, chitin, polyethylene glycol, lanolin, and edokine.

[0048] The whitening ingredients are preferably selected from one or more of the following: fruit acid, tranexamic acid, arbutin, vitamin C, niacinamide, kojic acid, phenylethyl resorcinol, ferulic acid, 3-o-ethyl ascorbic acid, ascorbate glucoside, potassium methoxysalicylate, resveratrol, and glucosinolate.

[0049] The anti-aging ingredients are preferably selected from one or more of the following: vitamin E, grape seed, peptides, polyphenols, vitamin C, carnosine, retinol, ergothioneine, conopeptide, coenzyme Q10, psoralen, ferulic acid, copper peptide, EGCE, ceramide, Panax notoginseng extract, niacinamide, jojoba oil, ubiquinone, and hyaluronic acid.

[0050] The sunscreen ingredient is preferably selected from one or more of the following: titanium dioxide, zinc oxide, ethylhexyl salicylate, oracrine, homosalate, butyl methoxydibenzoylmethane, and ethylhexyl methoxycinnamate.

[0051] The repairing ingredients shown are preferably selected from one or more of the following: panthenol, ceramide, centella asiatica extract, edokine, artemisia annua oil extract, astaxanthin extract, olive leaf extract, bisabolol, squalane, beta-glucan, and bifida ferment lysate;

[0052] The acne-removing ingredients are preferably selected from one or more of the following: salicylic acid, fruit acid, azelaic acid, centella asiatica extract, olive leaf extract, sulfonated shale oil, dragon's blood tree extract, tau phenol; and / or

[0053] The soothing ingredients are preferably selected from one or more of the following: Centella asiatica extract, chamomile extract, witch hazel extract, dipotassium glycyrrhizate, aloe vera extract, bisabolol, calendula extract, and purslane extract.

[0054] The fourth aspect of the present invention provides the use of the Panax notoginseng-Paris supramolecular complex described in the first aspect in the preparation of cosmetic products for anti-inflammatory, antibacterial, soothing or moisturizing purposes;

[0055] Preferably, the dosage form of the beauty product is selected from one or more of the following: cream, lotion, aqueous solution, gel, oil, powder, mud, aerosol, patch, and film;

[0056] More preferably,

[0057] The dosage form of the ointment / cream is selected from one or more of the following: ointment, cream, honey, grease.

[0058] The dosage form of the emulsion is selected from one or more of the following: milk, emulsion, milk, milk liquid.

[0059] The dosage form of the aqueous solution is selected from one or more of the following: dew, liquid, and water.

[0060] The dosage form of the gel is selected from one or more of the following: gel, jelly, and gum.

[0061] The dosage form of the powder is selected from one or more of the following: loose powder, granules, block powder, large solid, and / or

[0062] The dosage form of the patch or film is selected from one or more of the following: eye mask, eye patch, face mask, face sheet.

[0063] This invention provides a Panax notoginseng-Paris supramolecular material, which uses Panax notoginseng extract as the main molecule and encapsulates the Paris polyphylla extract using a high-pressure homogenization method to obtain a Panax notoginseng-Paris supramolecular material with high transdermal absorption, high water solubility and low cytotoxicity, in order to meet market requirements for Paris polyphylla extract products and improve the market competitiveness of the products.

[0064] This invention also provides a method for preparing supramolecular form of Paris polyphylla, the method comprising the following steps:

[0065] (1) The mass ratio of Paris polyphylla extract to Panax notoginseng extract is 1:1 to 1:600. The Paris polyphylla extract is prepared into a solution of 5 to 50 g / L using hot pure water at 70℃ to 80℃, and the Panax notoginseng extract is prepared into a solution of 10 to 100 g / L using pure water for later use.

[0066] The mass ratio of total saponins from Paris polyphylla to Panax notoginseng extract is 1:1 to 1:600, preferably 1:1 to 1:400, and more preferably 1:1 to 1:200; the concentration of Paris polyphylla extract is 1 to 200 g / L, preferably 1 to 100 g / L, and more preferably 5 to 50 g / L; the concentration of Panax notoginseng extract solution is 1 to 200 g / L, preferably 1 to 150 g / L, and more preferably 10 to 100 g / L.

[0067] (2) Mix the Paris polyphylla extract and Panax notoginseng extract solution and disperse them on a high-speed dispersion homogenizer at a speed of 3000-9000 r / min for 5-25 min to obtain Panax notoginseng-Paris polyphylla suspension.

[0068] The rotational speed is 0–10000 r / min, preferably 3000–10000 r / min, more preferably 3000–9000 r / min; the homogenization time is 0–60 min, preferably 5–40 min, more preferably 5–25 min.

[0069] (3) Transfer the Panax notoginseng-Paris polyphylla suspension into a high-pressure homogenizer and cycle it 5 to 20 times at a pressure of 200 to 700 Bar. Obtain the Panax notoginseng-Paris polyphylla supramolecular solution.

[0070] The pressure is 10 to 1500 Bar, preferably 100 to 1000 Bar, more preferably 200 to 700 Bar; the number of cycles is 1 to 30, preferably 5 to 25, more preferably 5 to 20.

[0071] (4) Dry the Panax notoginseng-Paris supramolecular solution to obtain Panax notoginseng-Paris supramolecular.

[0072] The drying method is selected from one or more of the following: vacuum freeze-drying, spray drying, and reduced pressure drying, preferably vacuum freeze-drying or spray drying, and most preferably vacuum freeze-drying.

[0073] The present invention also provides a cosmetic product for anti-inflammatory, antibacterial, soothing or moisturizing purposes, the cosmetic product comprising the Panax notoginseng-Paris supramolecular as described in the second aspect;

[0074] Preferably, the dosage form of the beauty product is selected from one or more of the following: cream, lotion, water, gel, oil, powder, mud, aerosol, patch, and film.

[0075] Preferably, the Panax notoginseng extract is an aqueous extract of Panax notoginseng root. The Panax notoginseng root is extracted by hydrothermal reflux, and the resulting extract is concentrated, precipitated with alcohol, and then dried to obtain the Panax notoginseng extract. The main components are Panax notoginseng polysaccharides and Panax notoginseng oligosaccharides.

[0076] Preferably, the Paris polyphylla extract is an alcohol extract of Paris polyphylla, the main component of which is Paris polyphylla saponin; the Paris polyphylla herb is extracted with alcohol, concentrated and then purified using D101 resin, and dried to obtain total Paris polyphylla saponins.

[0077] This invention provides a highly transdermal-absorbable Panax notoginseng-Paris supramolecular compound and its preparation method. Panax notoginseng extract and Paris polyphylla are prepared into an aqueous solution, mixed, homogenized under high pressure, and freeze-dried under vacuum to obtain a Panax notoginseng-Paris supramolecular compound in which Panax notoginseng extract encapsulates Paris polyphylla extract. This method has a simple process flow, is easy to control, produces stable granulation, and has low production costs. The Panax notoginseng-Paris supramolecular compound obtained by this method improves the water solubility of Paris polyphylla extract, increases its skin penetration, and reduces its cytotoxicity. This method utilizes the synergistic effect of the active ingredients, resulting in strong compatibility and synergistic efficacy. It also slows down the release time of the active ingredients and extends their shelf life.

[0078] The Panax notoginseng-Paris polyphylla supramolecular complex and its preparation method of the present invention may have, but are not limited to, the following beneficial effects:

[0079] 1. This invention employs a method of encapsulating active ingredients with active ingredients. Using Panax notoginseng extract, which has high safety, as a carrier, the extract of Paris polyphylla is encapsulated using a high-pressure homogenization method. The process is simple, requires no other excipients, and does not use organic solvents.

[0080] 2. The Panax notoginseng-Paris supramolecular obtained by this invention retains the high water solubility and skin permeability of Panax notoginseng extract, and reduces the cytotoxicity of Paris polyphylla extract, resulting in a novel supramolecular material with high water solubility, excellent skin permeability and low cytotoxicity, which is superior to similar products on the market.

[0081] 3. The Panax notoginseng extract and Paris polyphylla extract used in this invention have strong compatibility and play a synergistic role; they can also slow down the release time of active ingredients and extend their shelf life. Attached Figure Description

[0082] The embodiments of the present invention will now be described in detail with reference to the accompanying drawings, wherein:

[0083] Figure 1 Electron micrographs of the Panax notoginseng-Paris polyphylla supramolecular molecules and the raw materials are shown, indicating that the supramolecular molecules obtained using this method are spherical or ellipsoidal inclusions, clearly distinguishable from the raw materials. Figure 1 a~c represent the Panax notoginseng-Paris supramolecular C~E prepared in Examples 2-4, respectively; Figure 1 d represents Panax notoginseng polysaccharide A prepared in Example 1, which is an amorphous polymer; Figure 1 e represents the total saponins B from Paris polyphylla prepared in Example 1, which are flaky crystals. Figure 1 f and Figure 1 g is a mixture of total saponins from Paris polyphylla and extract from Panax notoginseng root in Comparative Example 1, or a conventional homogenized product that does not exhibit an encapsulated state and is a mixture of flaky crystals and polymers.

[0084] Figure 2 The transdermal absorption of Panax notoginseng-Paris supramolecular and Paris extract was demonstrated; Panax notoginseng-Paris supramolecular can significantly improve skin penetration efficiency, which shows a time-dependent effect within a certain time range (4h).

[0085] Figure 3 The diagram shows the supramolecular structure of Panax notoginseng and Paris polyphylla, in which Panax notoginseng extract is the host molecule and Paris polyphylla extract is the guest molecule. Panax notoginseng extract has a hydrophilic / hydrophobic cavity structure, and Paris polyphylla extract is embedded in it to form an ordered solid structure by non-covalent bonding, thereby forming a supraamphiphilic molecule with high water solubility, high skin permeability and low cytotoxicity. Detailed Implementation

[0086] The present invention will be further illustrated below with specific embodiments. However, it should be understood that these embodiments are merely for more detailed and specific illustration and should not be construed as limiting the present invention in any way.

[0087] This section provides a general description of the materials and testing methods used in the experiments of this invention. While many of the materials and methods of operation used to achieve the objectives of this invention are well known in the art, the invention is still described in as much detail as possible herein. It will be apparent to those skilled in the art that, unless otherwise stated in the context, the materials and methods of operation used in this invention are well known in the art.

[0088] The reagents and instruments used in the following examples are as follows:

[0089] Material:

[0090] Panax notoginseng, Paris polyphylla, Paris polyphylla var. globulus, and Paris polyphylla yunnanensis were purchased from Yunnan Baiyao Group Chinese Medicine Resources Co., Ltd.

[0091] Paris polyphylla saponin I and Paris polyphylla saponin H standards were purchased from Beijing Solarbio Science & Technology Co., Ltd.

[0092] instrument:

[0093] Heated magnetic stirrer, purchased from: Aika (Guangzhou) Instrument Equipment Co., Ltd.; Model: RCT basic.

[0094] Laser particle size analyzer, purchased from: Brookhaven Instruments, USA; Model: NanoBrook 90PlusZeta;

[0095] Digital display high-speed disperser: Purchased from: IKA (Guangzhou) Instrument Equipment Co., Ltd.; Model: IKA T18digital;

[0096] High-pressure homogenizer, purchased from: Ningbo Scientz Biotechnology Co., Ltd.; Model: Scientz-150;

[0097] Freeze dryer, purchased from: Ningbo Sscientz Biotechnology Co., Ltd.; Model: sscientz-50F;

[0098] Desktop scanning electron microscope, purchased from COXEM, South Korea; model: EM-30P.

[0099] Example 1

[0100] This embodiment illustrates the preparation of Panax notoginseng polysaccharide extract, Panax notoginseng oligosaccharide extract, and Paris polyphylla extract.

[0101] (1) Panax notoginseng polysaccharide extract: Take 1 kg of Panax notoginseng root, crush it, reflux extract it with 20 times the volume of water for 2 hours, repeat twice, combine the extracts, concentrate it under reduced pressure to form an extract, precipitate it with 85% alcohol, take the precipitate, dry it and crush it to obtain 146 g of Panax notoginseng polysaccharide A.

[0102] (2) Panax notoginseng oligosaccharide extract: Take 10 kg of Panax notoginseng roots, crush them, extract with 20 times the volume of 75% ethanol for 2 h, repeat twice, combine the extracts, concentrate to a certain volume, load onto macroporous resin, collect 10 L of waste liquid from rinsing the resin with water, concentrate under reduced pressure to obtain 2.3 kg of Panax notoginseng oligosaccharide A'.

[0103] (3) Paris polyphylla extract: Take 1 kg of Paris polyphylla granules, crush them, and extract them by reflux with 15 times the volume of 70% ethanol for 2 hours. Repeat twice, combine the extracts, concentrate them under reduced pressure to form an extract, purify with D101 resin, wash with 2 BV of water, collect the 95% ethanol eluent, concentrate under reduced pressure and dry to obtain 58 g of total saponins B from Paris polyphylla.

[0104] Unless otherwise stated, the extract prepared in Example 1 is used in all the following examples.

[0105] Example 2

[0106] This embodiment is an exemplary illustration of the Panax notoginseng-Paris polyphylla supramolecular complex and its preparation method.

[0107] (1) Weigh 2.5g of Panax notoginseng polysaccharide A prepared in Example 1 according to the mass ratio of Paris polyphylla extract to Panax notoginseng polysaccharide extract of 1:4, add 500mL of pure water to obtain Panax notoginseng polysaccharide extract solution; weigh 0.625g of Paris polyphylla total saponins B prepared in Example 1, add 65mL of hot pure water at 75±5℃ to obtain Paris polyphylla total saponin solution; shake well.

[0108] (2) Mix the total saponin solution of Paris polysaccharide obtained in step (1) and the polysaccharide extract solution of Panax notoginseng, and pre-disperse them for 15 min at 8000 r / min on a high-speed dispersion homogenizer to obtain a suspension.

[0109] (3) The suspension was transferred into a high-pressure homogenizer and circulated 15 times at a pressure of 500 Bar to obtain a Panax notoginseng polysaccharide-Paris polymorphic solution.

[0110] (4) The Panax notoginseng polysaccharide-Paris polymorphic solution was freeze-dried to obtain Panax notoginseng polysaccharide-Paris polymorphic complex C, 3.0 g.

[0111] (5) Take 5 mg of the Panax notoginseng polysaccharide-Paris polymorphic complex C prepared in step (4), prepare a solution of 1 mg / mL, filter it through a 0.45 μm nylon membrane, and detect its particle size, optical path and solution state.

[0112] (6) Encapsulation efficiency was determined using diosgenin as a reference. Referring to the 2020 edition of the Pharmacopoeia of the People's Republic of China, 100 mg of Panax notoginseng polysaccharide-Paris polymorphic complex C was weighed and placed in 3 ml of room temperature pure water. The mixture was vigorously shaken for 30 seconds every 5 min, and the dissolution was observed within 30 min.

[0113] (7) Coat the powder of Panax notoginseng polysaccharide-Paris supramolecular complex C, total saponins of Paris B, and Panax notoginseng polysaccharide A evenly onto the conductive core, spray gold to make the sample conductive, and then place it under a scanning electron microscope to observe the microstructure of the sample.

[0114] The particle size / PDI of the Panax notoginseng polysaccharide-Paris polymorph supramolecular complex C prepared according to this method was 203.5 nm / 0.196, with an encapsulation efficiency of 75.57%. Solubility tests showed that the prepared Panax notoginseng-Paris polymorph supramolecular solution was in the following state: dissolved, with no visible insoluble matter, clear solution, forming a colloidal solution with a clear optical path. Electron microscopy results (…) Figure 1 a) indicates that the Panax notoginseng polysaccharide-Paris polysaccharide supramolecular complex C forms a spherical or ellipsoidal structure; while the Panax notoginseng polysaccharide A prepared in Example 1 is an amorphous polymer (see Figure 1 d) The total saponins B from Paris polyphylla prepared in Example 1 are flaky crystals (see [link]). Figure 1 e).

[0115] Example 3

[0116] This embodiment is yet another exemplary illustration of the Panax notoginseng-Paris polyphylla supramolecular complex and its preparation method.

[0117] (1) Weigh 12.5g of the oligosaccharide A' prepared in Example 1 according to the mass ratio of Paris polyphylla extract to Panax notoginseng oligosaccharide extract of 1:20, add 500mL of pure water to obtain the oligosaccharide extract solution; weigh 0.625g of the total saponins B prepared in Example 1, add 65mL of hot pure water at 70±5℃ to obtain the total saponins solution; shake well.

[0118] (2) Mix the total saponin solution of Paris polyphylla and the oligosaccharide extract solution obtained in step (1), and pre-disperse them for 10 min at 9000 r / min on a high-speed dispersion homogenizer to obtain a suspension.

[0119] (3) The suspension obtained in step (2) is transferred into a high-pressure homogenizer and circulated 10 times under a pressure of 700 Bar to obtain a Panax notoginseng oligosaccharide-Paris polymorphic solution.

[0120] (4) Freeze-dry the Panax notoginseng oligosaccharide-Paris supramolecular solution obtained in step (3) to obtain Panax notoginseng oligosaccharide-Paris supramolecular complex D, 13.1g.

[0121] (5) Take 5 mg of the Panax notoginseng oligosaccharide-Paris polymorphic complex D prepared in step (4), prepare a solution of 1 mg / mL, filter it through a 0.45 μm nylon membrane, and detect its particle size, optical path and solution state.

[0122] (6) Encapsulation efficiency was determined using diosgenin as a reference. Referring to the 2020 edition of the Pharmacopoeia of the People's Republic of China, 100 mg of Panax notoginseng oligosaccharide-Paris polymorphic complex D was weighed and placed in 3 ml of room temperature pure water. The mixture was vigorously shaken for 30 seconds every 5 min, and the dissolution was observed within 30 min.

[0123] (7) Coat the powder of the Panax notoginseng oligosaccharide-Paris polymorphic complex D evenly onto the conductive core, spray gold to make the sample conductive, and then observe the microstructure of the sample under a scanning electron microscope.

[0124] The notoginseng oligosaccharide-Paris polyphylla supramolecular complex D prepared according to this method has a particle size / PDI ratio of 562.5 nm / 0.231 and an encapsulation efficiency of 77.12%. Solubility tests show that the prepared notoginseng-Paris polyphylla supramolecular solution is in the following state: dissolved, with no visible insoluble matter, clear solution, forming a colloidal solution with a clear optical path. Electron microscopy results (…) Figure 1 b) indicates that the Panax notoginseng oligosaccharide-Paris polymorphic supramolecular complex D forms a spherical or ellipsoidal structure.

[0125] Example 4

[0126] This embodiment is another exemplary illustration of the Panax notoginseng-Paris polyphylla supramolecular complex and its preparation method.

[0127] (1) Weigh 50g of Panax notoginseng polysaccharide A prepared in Example 1 according to the mass ratio of Paris polyphylla extract to Panax notoginseng polysaccharide extract of 1:80, add 800mL of pure water to obtain Panax notoginseng polysaccharide extract solution; weigh 0.625g of Paris polyphylla total saponins B prepared in Example 1, add 100mL of hot pure water at 75±5℃ to obtain Paris polyphylla total saponin solution; shake well.

[0128] (2) Mix the total saponin solution of Paris polysaccharide obtained in step (1) and the polysaccharide extract solution of Panax notoginseng, and pre-disperse them for 25 min at 5000 r / min on a high-speed dispersion homogenizer to obtain a suspension.

[0129] (3) The suspension obtained in step (2) was transferred into a high-pressure homogenizer and circulated 17 times under a pressure of 400 Bar to obtain a Panax notoginseng polysaccharide-Paris polymorphic solution.

[0130] (4) Freeze-dry the Panax notoginseng polysaccharide-Paris polymorphic solution obtained in step (3) to obtain Panax notoginseng polysaccharide-Paris polymorphic complex E, 50.5g.

[0131] (5) Take 5 mg of the Panax notoginseng polysaccharide-Paris polymorphic complex E prepared in step (4), prepare a solution of 1 mg / mL, filter it through a 0.45 μm nylon membrane, and detect its particle size, optical path and solution state.

[0132] (6) Encapsulation efficiency was determined using diosgenin as a reference. Referring to the 2020 edition of the Pharmacopoeia of the People's Republic of China, 100 mg of Panax notoginseng polysaccharide-Paris polymorphic complex E was weighed and placed in 3 ml of room temperature pure water. The mixture was vigorously shaken for 30 seconds every 5 min, and the dissolution was observed within 30 min.

[0133] (7) Coat the Powder E of the Panax notoginseng-Paris polymorphic complex evenly onto the conductive core, spray gold to make the sample conductive, and then observe the microstructure of the sample under a scanning electron microscope.

[0134] The particle size / PDI of the Panax notoginseng polysaccharide-Paris polymorph supramolecular complex E prepared according to this method was 358.5 nm / 0.291, with an encapsulation efficiency of 69.42%. Solubility tests showed that the prepared Panax notoginseng-Paris polymorph supramolecular solution was in the following state: dissolved, with no visible insoluble matter, clear solution, forming a colloidal solution with a clear optical path. Electron microscopy results (…) Figure 1 c) indicates that the Panax notoginseng polysaccharide-Paris polymorphic supramolecular complex E forms a spherical or ellipsoidal structure.

[0135] Example 5

[0136] This embodiment is yet another exemplary illustration of the Panax notoginseng-Paris polyphylla supramolecular complex and its preparation method.

[0137] (1) According to the mass ratio of Paris polysaccharide extract to Panax notoginseng polysaccharide extract of 1:200, weigh 80g of Panax notoginseng polysaccharide A prepared in Example 1, add 1200mL of pure water to obtain Panax notoginseng polysaccharide extract solution; weigh 0.4g of total saponins B prepared in Example 1, add 200mL of hot pure water at 75±5℃ to obtain total saponins solution of Paris polysaccharide; shake well.

[0138] (2) Mix the total saponin solution of Paris polysaccharide obtained in step (1) and the polysaccharide extract solution of Panax notoginseng, and pre-disperse them for 25 min at 5000 r / min on a high-speed dispersion homogenizer to obtain a suspension.

[0139] (3) The suspension obtained in step (2) was transferred into a high-pressure homogenizer and circulated 17 times under a pressure of 400 Bar to obtain a Panax notoginseng polysaccharide-Paris polymorphic solution.

[0140] (4) The Panax notoginseng polysaccharide-Paris polymorphic solution obtained in step (3) was freeze-dried to obtain Panax notoginseng polysaccharide-Paris polymorphic complex F, 79.4g.

[0141] (5) Take 5 mg of the Panax notoginseng polysaccharide-Paris polymorphic complex F prepared in step (4), prepare a solution of 1 mg / mL, filter it through a 0.45 μm nylon membrane, and detect its particle size, optical path and solution state.

[0142] (6) Encapsulation efficiency was determined using diosgenin as a reference standard. Referring to the 2020 edition of the Pharmacopoeia of the People's Republic of China, 100 mg of Panax notoginseng polysaccharide-Paris polymorphic complex F was weighed and placed in 3 ml of room temperature pure water. The mixture was vigorously shaken for 30 seconds every 5 min, and the dissolution was observed within 30 min.

[0143] The particle size / PDI of the Panax notoginseng polysaccharide-Paris polymorph supramolecular complex F prepared according to this method is 284.3 nm / 0.319, and the encapsulation efficiency is 72.6%. The solubility test shows that the prepared Panax notoginseng-Paris polymorph supramolecular solution is in the following state: dissolved, with no visible insoluble matter, clear solution, forming a colloidal solution with obvious light path.

[0144] Examples 6-8

[0145] This embodiment is another exemplary illustration of the Panax notoginseng-Paris polyphylla supramolecular complex.

[0146] The preparation methods of the Panax notoginseng-Paris polymorphic complexes in Examples 6-8 are the same as those in Example 2, with the differences shown in Table 1. In Example 8, the Panax notoginseng oligosaccharide-Paris polymorphic total saponins contain Panax notoginseng oligosaccharide A' prepared in Example 1.

[0147] Table 1. Panax notoginseng-Paris polyphylla supramolecular complexes prepared in Examples 6-8

[0148]

[0149] Table 2. Particle size, encapsulation efficiency, and solution state of the Panax notoginseng-Paris polyphylla supramolecular complexes G-J in Examples 6-8

[0150]

[0151]

[0152] As shown in Table 2, the particle size, encapsulation efficiency and solubility tests of the Panax notoginseng-Paris polymorph supramolecular complexes G to J prepared according to this method show that the prepared Panax notoginseng-Paris polymorph supramolecular solution is in the following state: dissolved, with no visible insoluble matter, clear solution, forming a colloidal solution, and with a clear light path.

[0153] Experimental Example 1

[0154] This example illustrates the cytotoxicity assay of the Panax notoginseng-Paris polyphylla supramolecular complex. Details are as follows:

[0155] (1) Immortalized epidermal cells (HaCaT) in the logarithmic growth phase were injected with 1×10 4 Inoculate at a density of 100 cells / mL into 96-well plates and incubate overnight at 37°C in a 5% CO2 environment.

[0156] (2) Different concentrations of sample solutions (Panax notoginseng polysaccharide A, Panax notoginseng oligosaccharide A', total saponins of Paris polyphylla B, Panax notoginseng polysaccharide-Paris polyphylla supramolecular complex C, Panax notoginseng oligosaccharide-Paris polyphylla supramolecular complex D, Panax notoginseng polysaccharide-Paris polyphylla supramolecular complex E, and Panax notoginseng oligosaccharide-Paris polyphylla supramolecular complex J) were added to each sample, with seven different concentrations and five replicates for each concentration. The cell control group was not treated, and the cells were cultured for another 48 hours. 10 μL of CCK8 solution was added to each well, and after culturing for 2.5 hours, the absorbance of each well was measured at 450 nm. Cell viability was calculated.

[0157] The experimental results are shown in Table 3. Panax notoginseng extract A showed no cytotoxic activity below 200 μg / mL. Total saponins B from *Paris polyphylla* showed strong cytotoxicity; at a concentration of 6.75 μg / mL, the cell survival rate was 80%. After preparing the supramolecular complex, at the same concentration of total saponins from *Paris polyphylla*, the supramolecular complex exhibited even lower cytotoxicity. The concentration of total saponins from *Paris polyphylla* corresponding to 80% cell survival was 89–91 μg / mL, a reduction of more than 13-fold. This indicates that the cytotoxicity of the Panax notoginseng-*Paris polyphylla* supramolecular complex prepared using this method is significantly reduced.

[0158] Table 3 shows the cytotoxicity results of the products prepared in Examples 1-4 and 8.

[0159]

[0160]

[0161] (Note: " / " indicates that there is no cytotoxic effect below 200 μg / mL)

[0162] Therefore, the supramolecular complexes prepared by this method (supramolecular complex FH prepared in Examples 5-7) can also effectively reduce the cytotoxicity of the compound and increase the amount of the compound used.

[0163] Experimental Example 2

[0164] This experimental example is used to illustrate the transdermal absorption effect of the products prepared in Examples 1-4 and Example 8.

[0165] (1) This experiment used porcine epidermal tissue and, based on the Franz diffusion cell, studied the transdermal absorption capacity of the Panax notoginseng polysaccharide-Paris polysaccharide supramolecular complexes C-E and Panax notoginseng oligosaccharide-Paris polysaccharide supramolecular complex J prepared in Examples 2-4 and Example 8.

[0166] (2) Prepare a 0.5 mg / mL solution from 25 mg of total saponins B from Paris polysaccharide, and prepare a 50 mg / mL solution from 0.5 g of polysaccharide-Paris supramolecular complex C, oligosaccharide-Paris supramolecular complex D, polysaccharide-Paris supramolecular complex E, and oligosaccharide-total saponins supramolecular complex J from Paris polysaccharide for later use.

[0167] (3) Take 4 mL of the solution prepared in step (2) and apply it to the epidermal tissue. After 12 hours, collect the skin sample and perform histological examination to detect the total saponin content of Paris polyphylla.

[0168] The experimental results are shown in Table 4: Almost all total saponins from Paris polyphylla could not penetrate the skin; approximately 2.49% of the saponins permeated the epidermis after 12 hours, with 3.93% remaining. However, after preparing the supramolecular complex using this method, the transdermal absorption rate significantly increased, with the transdermal efficiency increasing by more than 6.5 times. This indicates that the supramolecular complex prepared in this invention has excellent transdermal absorption performance.

[0169] Table 4 shows the transdermal absorption effects of supramolecular complexes CE and J and Paris polyphylla extract B prepared in Examples 1-4 and 8.

[0170]

[0171] Therefore, the supramolecular complexes prepared by this method (supramolecular complexes FI prepared in Examples 5-7) also have good transdermal absorption effects.

[0172] Experimental Example 3

[0173] This experimental example uses fluorescence microscopy to examine the localization of the Panax notoginseng-Paris polyphylla supramolecular complex in the skin and to measure the transdermal absorption of the supramolecular complex.

[0174] This experimental example uses the Panax notoginseng polysaccharide-Paris polymorph supramolecular complex C prepared in Example 2 as an example.

[0175] (1) Coumarin-6 was used to fluorescently label the Panax notoginseng-Paris supramolecular complex to prepare 10 μg / ml coumarin-6 labeled Panax notoginseng-Paris nanoparticles.

[0176] (2) The transdermal localization performance of the nanoparticle group compared with that of free coumarin-6 at the same concentration was examined using the diffusion cell method. The transdermal fluorescence of each group was detected at 1, 2 and 4 h. After freezing, the tissue cell nuclei were labeled with Hochest (longitudinal section of skin), and the fluorescence position and intensity were observed under a confocal microscope to determine the localization of the nanoparticles in the skin.

[0177] The test results are as follows Figure 2As shown, the Panax notoginseng polysaccharide-Paris polymorphic complex C prepared in Example 2 can significantly improve skin penetration efficiency, exhibiting time dependence within a certain time range (4h).

[0178] Based on particle size, encapsulation efficiency, and solution state, the Panax notoginseng-Paris polyphylla supramolecular complexes prepared in Examples 3-8 can also significantly improve skin penetration efficiency.

[0179] Comparative Example 1

[0180] This comparative example is used to compare the mixing method, the ordinary homogenization method, and the Panax notoginseng-Paris supramolecular complex of the present invention.

[0181] (1) Take 12.5g of Panax notoginseng polysaccharide A prepared in Example 1 and 0.625g of Paris polysaccharide B prepared in Example 1, shake and mix to obtain mixture 1.

[0182] (2) Weigh 12.5g of Panax notoginseng polysaccharide A prepared in Example 1, add 500mL of pure water to obtain Panax notoginseng polysaccharide extract solution; weigh 0.625g of Paris polyphylla total saponins B prepared in Example 1, add 65mL of hot pure water at 70-80℃ to obtain Paris polyphylla extract solution; shake well. After mixing, homogenize on a high-speed dispersion homogenizer at 9000r / min for 20min to obtain a suspension. Dry to obtain mixture 2.

[0183] (3) Coat mixture 1 and mixture 2 evenly onto the conductive core, spray gold to make the sample conductive, and then place it under a scanning electron microscope to observe the microstructure of the sample.

[0184] The results are as follows Figure 1 f and Figure 1 As shown in g, both mixture 1 and mixture 2 contain platy crystals and amorphous substances, while these structures are absent in the supramolecular structure, which contains only spherical or ellipsoidal inclusions.

[0185] In summary, the Panax notoginseng-Paris polyphylla supramolecular complex prepared by the method of this invention has uniform particle size, forming spherical or ellipsoidal inclusions with a size of 200-500 nm and a PDI < 0.3; the encapsulation efficiency is > 65%; it is stable in aqueous solution, has high solubility, no visible insoluble matter, clear solution, obvious light path, and forms colloidal solution; its cytotoxicity is significantly reduced compared to an equal amount of total Paris polyphylla saponins, and 13 times lower than that of total Paris polyphylla saponins in spherical drug-coated formulations (80% cell survival rate); the transdermal absorption rate is significantly increased.

[0186] While the effects of some embodiments have been shown above, those skilled in the art should understand that, based on the concept of the present invention, the other embodiments described above, without specifically showing effects, can also achieve the following technical effects as stated in the summary of the invention:

[0187] 1. This invention employs a method of encapsulating active ingredients with active ingredients. Using Panax notoginseng extract, which has high safety, as a carrier, the extract of Paris polyphylla is encapsulated using a high-pressure homogenization method. The process is simple, requires no other excipients, and does not use organic solvents.

[0188] 2. The Panax notoginseng-Paris supramolecular obtained by this invention retains the high water solubility and skin permeability of Panax notoginseng extract, and reduces the cytotoxicity of Paris polyphylla extract, resulting in a novel supramolecular material with high water solubility, excellent skin permeability and low cytotoxicity, which is superior to similar products on the market.

[0189] 3. The Panax notoginseng extract and Paris polyphylla extract used in this invention have strong compatibility and play a synergistic role; they can also slow down the release time of active ingredients and extend their shelf life.

[0190] Although the invention has been described to a certain extent, it is apparent that appropriate variations can be made to the various conditions without departing from the spirit and scope of the invention. It is understood that the invention is not limited to the described embodiments, but falls within the scope of the claims, which include equivalent substitutions for each of the elements.

Claims

1. A Panax notoginseng-Paris polyphylla supramolecular complex, characterized in that, The Panax notoginseng-Paris polyphylla supramolecular complex is a complex formed by non-covalent bonding of Panax notoginseng extract as the host molecule and Paris polyphylla extract as the guest molecule, wherein the host molecule encapsulates the guest molecule structure. The particle size of the Panax notoginseng-Paris polyphylla supramolecular complex is 100-1000 nm, preferably 200-900 nm, more preferably 200-870 nm, and most preferably 200-500 nm. Preferably, the Panax notoginseng extract is a water extract of Panax notoginseng, more preferably a polysaccharide extract or oligosaccharide extract of Panax notoginseng obtained by water extraction; and / or Preferably, the Paris polyphylla extract is an alcoholic extract of Paris polyphylla, and its main components are preferably selected from one or more of the following: total saponins of Paris polyphylla, saponin I, saponin II, diosgenin, saponin V, saponin VI, saponin VII, saponin H, diosgenin, and saponin D; more preferably selected from one or more of the following: total saponins of Paris polyphylla, saponin I, saponin II, saponin VI, saponin VII, and saponin H; even more preferably selected from one or more of the following: total saponins of Paris polyphylla, saponin I, saponin VII, and saponin H; and even more preferably selected from one or more of the following: total saponins of Paris polyphylla, saponin H, and saponin I.

2. The Panax notoginseng-Paris polyphylla supramolecular complex according to claim 1, characterized in that: The Panax notoginseng-Paris polyphylla supramolecular complex is a spherical or ellipsoidal inclusion; The PDI of the Panax notoginseng-Paris polyphylla supramolecular complex is <0.5, preferably <0.45, more preferably <0.4, and most preferably <0.3; The encapsulation efficiency of the Panax notoginseng-Paris polyphylla supramolecular complex is >65%, preferably >70%, more preferably >75%; and / or The mass ratio of the guest molecule to the host molecule is 1:1 to 800, preferably 1:1 to 600, and more preferably 1:4 to 600.

3. The Panax notoginseng-Paris polyphylla supramolecular complex according to claim 1 or 2, characterized in that: The Paris polyphylla extract is selected from one or more of the following: Paris polyphylla longipeta extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract, Paris polyphylla var. chinensis extract; and / or The Panax notoginseng extract is selected from one or more of the following: Panax notoginseng stem and leaf water extract, Panax notoginseng root water extract, Panax notoginseng flower extract, Panax notoginseng whole plant water extract, preferably Panax notoginseng root water extract or Panax notoginseng whole plant water extract, and most preferably Panax notoginseng root water extract.

4. A method for preparing the Panax notoginseng-Paris polyphylla supramolecular complex according to any one of claims 1 to 3, characterized in that, The method includes the following steps: (1) Prepare the guest molecule Paris polyphylla extract solution and the host molecule Panax notoginseng extract solution respectively; (2) The guest molecule Paris polyphylla extract solution and the host molecule Panax notoginseng extract solution prepared in step (1) are mixed and dispersed and homogenized at high speed to obtain a host-guest suspension. (3) The host-guest suspension prepared in step (2) was homogenized under high pressure to obtain a host-guest supramolecular solution; and (4) The host-guest supramolecular solution prepared in step (3) is dried to obtain the supramolecular complex.

5. The method according to claim 4, characterized in that, In step (1): When the main molecule is Panax notoginseng aqueous extract, the preparation method of the main molecule Panax notoginseng extract solution includes: adding pure water to the Panax notoginseng aqueous extract to obtain the main molecule solution; and / or When the guest molecule is a Paris polyphylla ethanol extract, the preparation method of the guest molecule Paris polyphylla extract solution includes: adding pure water at 50℃~90℃, preferably pure water at 70℃~80℃, to the Paris polyphylla ethanol extract to obtain the guest molecule solution.

6. The method according to claim 4 or 5, characterized in that, In step (1): The concentration of the main molecule, Panax notoginseng extract solution, is 1–200 g / L, preferably 1–150 g / L, more preferably 10–100 g / L; and / or The concentration of the guest molecule Paris polyphylla extract solution is 1–200 g / L, preferably 1–100 g / L, and more preferably 5–50 g / L.

7. The method according to any one of claims 4 to 6, characterized in that, In step (2): The homogenization rotation speed is 0–10000 r / min, preferably 3000–10000 r / min, more preferably 3000–9000 r / min; and / or The homogenization time is 0–60 min, preferably 5–40 min, and more preferably 10–25 min.

8. The method according to any one of claims 4 to 7, characterized in that: In step (3): The pressure of the high-pressure homogenizer is 10 to 1500 Bar, preferably 100 to 1000 Bar, and more preferably 400 to 700 Bar; The homogenization cycle is 1 to 30 times, preferably 5 to 25 times, more preferably 10 to 20 times; and / or In step (4), the drying method is selected from one or more of the following: vacuum freeze drying, spray drying, and reduced pressure drying, preferably vacuum freeze drying or spray drying, and most preferably vacuum freeze drying.

9. A beauty product, characterized in that, The beauty product comprises the Panax notoginseng-Paris supramolecular complex as described in any one of claims 1 to 3; Preferably, the beauty product further comprises one or more of the following: moisturizing ingredients, whitening ingredients, anti-aging ingredients, sun protection ingredients, repairing ingredients, acne-reducing ingredients, and soothing ingredients; wherein: The moisturizing ingredients are preferably selected from one or more of the following: hyaluronic acid, amino acids, provitamin B, allantoin, ceramide, hyaluronic acid, glycerin, sodium alginate, tremella polysaccharide, seaweed polysaccharide, squalane, beta-glucan, sodium pyrrolidone carboxylate, collagen, lactic acid, petrolatum, chitin, polyethylene glycol, lanolin, and edokine. The whitening ingredients are preferably selected from one or more of the following: fruit acid, tranexamic acid, arbutin, vitamin C, niacinamide, kojic acid, phenylethyl resorcinol, ferulic acid, 3-o-ethyl ascorbic acid, ascorbate glucoside, potassium methoxysalicylate, resveratrol, and glucosinolate. The anti-aging ingredients are preferably selected from one or more of the following: vitamin E, grape seed, peptides, polyphenols, vitamin C, carnosine, retinol, ergothioneine, conopeptide, coenzyme Q10, psoralen, ferulic acid, copper peptide, EGCE, ceramide, Panax notoginseng extract, niacinamide, jojoba oil, ubiquinone, and hyaluronic acid. The sunscreen ingredient is preferably selected from one or more of the following: titanium dioxide, zinc oxide, ethylhexyl salicylate, oracrine, homosalate, butyl methoxydibenzoylmethane, and ethylhexyl methoxycinnamate. The repairing ingredients shown are preferably selected from one or more of the following: panthenol, ceramide, centella asiatica extract, edokine, artemisia annua oil extract, astaxanthin extract, olive leaf extract, bisabolol, squalane, beta-glucan, and bifida ferment lysate; The acne-removing ingredients are preferably selected from one or more of the following: salicylic acid, fruit acid, azelaic acid, centella asiatica extract, olive leaf extract, sulfonated shale oil, dragon's blood tree extract, tau phenol; and / or The soothing ingredients are preferably selected from one or more of the following: Centella asiatica extract, chamomile extract, witch hazel extract, dipotassium glycyrrhizate, aloe vera extract, bisabolol, calendula extract, and purslane extract.

10. The use of the Panax notoginseng-Paris supramolecular complex according to any one of claims 1 to 3 in the preparation of cosmetic products for anti-inflammatory, antibacterial, soothing or moisturizing purposes; Preferably, the dosage form of the beauty product is selected from one or more of the following: cream, lotion, aqueous solution, gel, oil, powder, mud, aerosol, patch, and film; More preferably, The dosage form of the ointment / cream is selected from one or more of the following: ointment, cream, honey, grease. The dosage form of the emulsion is selected from one or more of the following: milk, emulsion, milk, milk liquid. The dosage form of the aqueous solution is selected from one or more of the following: dew, liquid, and water. The dosage form of the gel is selected from one or more of the following: gel, jelly, and gum. The dosage form of the powder is selected from one or more of the following: loose powder, granules, block powder, large solid, and / or The dosage form of the patch or film is selected from one or more of the following: eye mask, eye patch, face mask, face sheet.

Images